TP53 Mutations Are Associated With Unfavorable Prognosis in CLL
Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma
Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL